Antigen News and Research

RSS

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Omicron infection induces cross-reactive immune responses

New research revealed that vaccine-breakthrough infections might elicit cross-reactive bNAbs against all variants of concern.

31 Dec 2021

SARS-CoV-2 omicron variant may be less severe than the delta variant

A new study reveals that omicron infections in South Africa are associated with lower rates of hospital admissions and lower disease severity compared to beta and delta infections.

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

Johns Hopkins Medicine urges people seeking COVID-19 testing not to enter emergency rooms

As the omicron variant of the COVID-19 coronavirus quickly spreads throughout the Baltimore-Washington, D.C., region, Johns Hopkins Medicine reminds those seeking COVID-19 testing that emergency rooms are for emergencies only.

30 Dec 2021

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Researchers carried out an analytical susceptibility test with cultured SARS-CoV-2 Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs).

29 Dec 2021

Researchers use rapid antigen testing to identify optimum isolation scenarios in COVID-19 infection

In a new study, researchers have been modeling different isolation scenarios to identify the most effective methods.

29 Dec 2021

Third BNT162b2 dose effectively neutralizes SARS-CoV-2 Omicron pseudovirus

The findings reveal that the Omicron neutralizing titers induced by the third vaccine dose are comparable to that achieved against the original Wuhan strain (wild-type SARS-CoV-2) by the two-dose regimen. The study is currently available on the medRxiv* preprint server while awaiting peer review.

28 Dec 2021

Pfizer-BioNTech booster shot may offer better immunity than a two-dose regimen

A new study suggests that the immune response against severe acute respiratory syndrome coronavirus 2 is greater with a three-dose regimen than a two-dose regimen.

24 Dec 2021

Decline in protection against SARS-CoV-2 Omicron in prior infected and fully vaccinated

In a recent study posted to the medRxiv* preprint server, researchers investigated the distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants among coronavirus disease 2019 (COVID-19) positive individuals who were either naive, fully vaccinated, or had a previous infection to further investigate possible escape from vaccine- or infection-induced immunity by Omicron compared to Delta.

22 Dec 2021

More breakthrough infections but less severe COVID-19 with Omicron

In a recent study posted to the bioRxiv* pre-print server, an international team of researchers reported the occurrence of coronavirus disease 2019 (COVID-19) breakthrough infections (BTIs) among health care workers (HCWs) participating in a phase III vaccine trial in Sisonke, South Africa.

22 Dec 2021